Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

bling symptom of advanced prostate cancer, and pain control is a key measurement of clinical benefit."

The planned initiation of this Phase 3 trial evaluating pain palliation is supported by encouraging Phase 2 data from patients receiving OGX-011 plus docetaxel as second-line chemotherapy - additional data was presented at the 2009 Annual Meeting of the American Urological Association (AUA). Based on the 27 patients who had prostate cancer-related pain and received OGX-011 plus docetaxel as second-line chemotherapy, 12 patients or 44% of patients, experienced pain palliation for 3 months or longer. The majority of pain responses occurred within the first two cycles of OGX-011 plus docetaxel. These data compare favorably even when compared to pain responses observed after first-line chemotherapy. This is clinically relevant because patients receiving second-line treatment have more advanced disease and are thought to have more profound or resistant prostate cancer-related pain.

About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung and breast cancer. OncoGenex Pharmaceuticals announced preliminary data on December 3, 2008 that OGX-011 showed an overall survival advantage in a randomized, controlled Phase 2 trial in first-line treatment of metastatic castrate resistant prostate cancer, in which the median survival for patients receiving OGX-011 in combination with docetaxel and prednisone was 27.5 months, compared to 16.9 months in patients receiving docetaxel and prednisone alone. Updated survival results will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology.

At the 2008 Annual Meeting of the American Society of Clinical Oncology, OncoGenex reported Phase 2 data with OGX-011 in combination with second-line treatment of metast
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:7/27/2015)... ... 2015 , ... This is a professional and in-depth study ... of the industry including definitions, classifications, applications and industry chain structure. The Biophotonics ... analysis, and key regions development status. Development policies and plans are discussed as ...
(Date:7/27/2015)... , July 27, 2015   Inocucor ... produces sustainable biological accelerators for farmers, has received ... and Trademark Office for its patent application to ... accelerate plant growth and enhance yields on farms ... relates to Inocucor,s live IN-M1 microbial consortium and ...
(Date:7/27/2015)... July 27, 2015 According to the ... (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug ... Europe , Asia-Pacific , Rest ... global biopreservation media market was valued at $247.7 million in ... by 2019, at a CAGR of 18.2% between 2014 and ...
Breaking Biology Technology:Amgen Announces Webcast of 2015 Second Quarter Financial Results 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3
... SEATTLE, March 9 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ... for the year and quarter ended December 31, 2008. , ... $7.1 million, or $0.37 per basic and $0.36 per diluted ... $1.04 per basic and diluted share, for the year ended ...
... YORK, March 9 As the global life sciences ... percent of executives surveyed from companies with revenues of ... to institute significant changes across the whole organization to ... a new white paper released by Deloitte Touche Tohmatsu ...
... More of What They Want: Efficiency, Data Quality, ... March 9 Against a backdrop of a ... WAT ) is demonstrating how its industry-leading analytical ... greatest scientific and business challenges at the 60th ...
Cached Biology Technology:Oncothyreon reports full year and fourth quarter 2008 financial results 2Oncothyreon reports full year and fourth quarter 2008 financial results 3Oncothyreon reports full year and fourth quarter 2008 financial results 4Oncothyreon reports full year and fourth quarter 2008 financial results 5Oncothyreon reports full year and fourth quarter 2008 financial results 6Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 2Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 3Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 4Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 5Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 2Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 3Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 4Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 5Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 6Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009 7
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... by Michigan State University biochemists helps explain how ... lead to discoveries related to plant tolerance for ... together two classic problems in plant biology," said ... biology. "One is that plants protect themselves against ...
... of neutron research at Indiana University Bloomington has received ... Standards and Technology. A recently awarded NIST grant provides ... to support cooperative research activities between the Low Energy ... Center for Neutron Research, located in Gaithersburg, Md. ...
... cover story of the most recent issue of National ... (UM) led expedition to the underwater caves of the ... are one of the least understood ecosystems on the ... these extreme environments, which include complete darkness, dramatic reversing ...
Cached Biology News:Researchers discover novel mechanism protecting plants against freezing 2IU physics facility awarded $5 million for cooperative neutron research 2National Geographic features University of Miami's work on Bahamas 'blue holes' 2National Geographic features University of Miami's work on Bahamas 'blue holes' 3
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
... Ferrofluid products perform optimally when ... Systems MagCellect Magnet. To accommodate ... iron boron permanent magnet holds ... mm test tubes or two ...
Request Info...
Form: Concentrated Applications: ELISA...
Biology Products: